Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Aegerion Pharmaceuticals Inc. (AEGR): Broadfin Capital Raises Its Stake Ahead of Merger

Page 1 of 10

Back in June, Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Qlt Inc. and the latter’s subsidiary, Isotope Acquisition Corp., entered into an Agreement and Plan of Merger which would merge Aegerion Pharmaceuticals and Isotope Acquisition into one company, with the resulting company becoming an indirect subsidiary of QLT (which is scheduled to change its name to Novelion Therapeutics Inc). Soon after the finalization of the merger, and pursuant to the conditions of the Merger Agreement, Novelion shall add one person to its Board of Directors, as proposed by Aegerion Pharmaceuticals (NASDAQ:AEGR).

A newly-amended 13D filing with the SEC revealed that Kevin Kotler of Broadfin Capital will become a Director of Novelion upon the finalization of the Merger. The filing also showed that Broadfin Capital has raised its stake in Aegerion Pharmaceuticals (NASDAQ:AEGR) to 4.29 million shares, which represent 14.52% of the company’s outstanding stock. Previously, the fund held 4.01 million shares, as per its 13F filing for the reporting period of June 30.

As its name suggests, Aegerion Pharmaceuticals is a biopharmaceutical company that works on discovering and producing various therapeutics to help patients who suffer from rare illnesses. Year-to-date, the company’s stock is down by 82.48%. In its financial report for the June quarter, Aegerion Pharmaceuticals disclosed a loss per share of $0.72, worse than the estimates of a loss per share of $0.60, and revenue of $44.5 million, topping the estimates of $35.5 million.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

Out of the 749 hedge funds tracked by Insider Monkey which filed 13Fs for the June quarter, 13 were bullish on Aegerion Pharmaceuticals (NASDAQ:AEGR), down by one investor from the previous filing period. Among the investors who reported long positions in the company were Ken Griffin’s Citadel Investment Group, which held a position in bonds worth around $4.51 million, Andy Redleaf’s Whitebox Advisors, with a position valued at $2.23 million, Jim Simons’ Renaissance Technologies, and Gavin Saitowitz and Cisco J. Del Valle’s Springbok Capital.

Some of the investors who dumped Aegerion Pharmaceuticals (NASDAQ:AEGR) during the June quarter were Andre F. Perold’s HighVista Strategies, which dropped its position valued at $936,000 at the end of March, Dmitry Balyasny’s Balyasny Asset Management, which said goodbye to $141,000 worth of Aegerion Pharmcatucals’ shares, and Matthew Tewksbury’s Stevens Capital Management.

Follow Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)
Trade (NASDAQ:AEGR) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Broadfin Capital 0 4,286,291 0 4,286,291 14.52%
Broadfin Healthcare Master Fund, Ltd 0 4,286,291 0 4,286,291 14.52%
Kevin Kotler 0 4,286,291 0 4,286,291 14.52%

Kevin Kotler
Kevin Kotler
Broadfin Capital

Page 1 of 10 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*
Aegerion Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
00767E102
(CUSIP Number)
Broadfin Capital, LLC
300 Park Avenue, 25th Floor
New York, New York 10022
Telephone- (212) 808-2460
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
September 9, 2016
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d‑1(f) or 240.13d-1(g), check the following box [  ].
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.
*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)
Trade (NASDAQ:AEGR) Now!
Page 1 of 10

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!